FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $462,590 | -44.1% | 218,203 | +25.4% | 0.00% | -66.7% |
| Q2 2023 | $827,954 | +104.5% | 173,940 | +144.9% | 0.00% | +200.0% |
| Q1 2023 | $404,780 | -57.2% | 71,014 | -24.3% | 0.00% | -66.7% |
| Q4 2022 | $946,816 | +144.0% | 93,837 | +442.4% | 0.00% | +50.0% |
| Q3 2022 | $388,000 | -46.6% | 17,300 | +39.2% | 0.00% | 0.0% |
| Q4 2021 | $727,000 | +42.0% | 12,430 | +100.1% | 0.00% | 0.0% |
| Q1 2021 | $512,000 | -92.9% | 6,212 | -92.2% | 0.00% | -93.8% |
| Q4 2020 | $7,213,000 | +71.4% | 79,323 | -24.7% | 0.03% | +88.2% |
| Q3 2020 | $4,209,000 | +351.6% | 105,300 | +287.6% | 0.02% | +240.0% |
| Q2 2020 | $932,000 | – | 27,167 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |